Sanofi/Regeneron’s Libtayo set for new skin cancer useSanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings Share XSanofi/Regeneron’s Libtayo set for new skin cancer usehttps://pharmaphorum.com/news/sanofi-regenerons-libtayo-set-for-new-skin-cancer-use/
Almirall strikes option deal to buy Bioniz and dermatology drug BNZ-1Almirall has begun an option agreement with California’s Bioniz, which could see it buy the entire company and Share XAlmirall strikes option deal to buy Bioniz and dermatology drug BNZ-1https://pharmaphorum.com/news/almirall-strikes-option-deal-to-buy-bioniz-and-dermatology-drug-bnz-1/
Smartphone app provides skin cancer early warning serviceThe makers of a smartphone app are hoping that it could be used to play a crucial role Share XSmartphone app provides skin cancer early warning servicehttps://pharmaphorum.com/news/smartphone-app-provides-skin-cancer-early-warning-service/
Immediately after EU nod, England’s NHS funds Sanofi skin cancer drugPatients in England will be among those who are first to benefit from Sanofi and Regeneron’s new cancer Share XImmediately after EU nod, England’s NHS funds Sanofi skin cancer drughttps://pharmaphorum.com/news/immediately-after-eu-nod-englands-nhs-funds-sanofi-skin-cancer-drug/
InflaRx flatlines after skin disease drug flops in midstage trialShares in German biotech InflaRx have plummeted 92% after it reported a comprehensive miss for its lead drug Share XInflaRx flatlines after skin disease drug flops in midstage trialhttps://pharmaphorum.com/news/inflarx-flatlines-skin-disease-drug-midstage-trial/
NHS funds BMS’ Opdivo to prevent skin cancer returningNICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer Share XNHS funds BMS’ Opdivo to prevent skin cancer returninghttps://pharmaphorum.com/news/nhs-funds-bms-opdivo-to-prevent-skin-cancer-returning/
Quality of life increasingly important in skin cancer, say doctors at this year’s ESMOThe factors a doctor should consider when choosing between therapies that could cure patients with skin cancer proved Share XQuality of life increasingly important in skin cancer, say doctors at this year’s ESMOhttps://pharmaphorum.com/views-analysis-oncology/quality-of-life-increasingly-important-in-skin-cancer-esmo/
EU regulators back BMS’ Opdivo in new skin cancer useBristol-Myers Squibb’s cancer immunotherapy Opdivo is likely to gain another use in Europe after regulators recommended it after Share XEU regulators back BMS’ Opdivo in new skin cancer usehttps://pharmaphorum.com/news/eu-regulators-back-bms-opdivo-in-new-skin-cancer-use/
Incyte shares down sharply after phase 3 skin cancer trial failureTrial tested epacadostat pill in combination with Merck & Co’s Keytruda Share XIncyte shares down sharply after phase 3 skin cancer trial failurehttps://pharmaphorum.com/news/incyte-shares-down-sharply-after-phase-3-skin-cancer-trial-failure/